BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

  Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial.

  March 14, 2022

   · 

  45 min read
• Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

  Can-Fite BioPharma Ltd today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (PTO) for its invention titled “Method for Treating Fibrotic Liver Tissue Using CL-IB MECA”.

  March 14, 2022

   · 

  7 min read
• Apyx Medical Corporation Notified of Pending FDA Medical Device Safety Communication Related to its Advanced Energy Products

  Apyx Medical Corporation Notified of Pending FDA Medical Device Safety Communication Related to its Advanced Energy Products.

  March 14, 2022

   · 

  6 min read
• Drug Development

  Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

  Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink ™ Therapy.

  March 14, 2022

   · 

  4 min read
• Biotech Bay

  Potrero Medical CEO Joe Urban to Present at 2022 LSI Emerging MedTech Summit

  Potrero Medical, announced today that Joe Urban , Potrero’s Chief Executive Officer, has been invited to present at the 2022 Life Science Intelligence (LSI) Emerging MedTech Summit on Thursday, March 17.

  March 14, 2022

   · 

  1 min read
• Business

  NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

  NexImmune, Inc. today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health.

  March 14, 2022

   · 

  4 min read
• Business

  Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021.

  March 14, 2022

   · 

  12 min read
• Drug Development

  BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

  BridgeBio Pharma, Inc. today announced positive data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i).

  March 14, 2022

   · 

  9 min read
• Pharm Country

  Dante Labs unveils Dante Genomics, the Company’s B2B global online marketplace delivering genomic solutions for medical professionals, researchers and pharma

  Dante Labs today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.

  March 14, 2022

   · 

  2 min read
• Drug Development

  Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022

  Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study.

  March 14, 2022

   · 

  6 min read